IQVIA (IQV)
(Delayed Data from NYSE)
$234.88 USD
+0.90 (0.38%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $234.90 +0.02 (0.01%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth A Momentum B VGM
Company Summary
Headquartered in Durham, NC., IQVIA Holdings Inc. provides advanced analytics, technology solutions and contract research services to the life sciences industry. The company was formed through the merger of IMS Health (RX) and Quintiles. The company is focused on helping healthcare clients to better serve patients by bringing in updated and innovative ideas in the process of clinical development and commercialization, speed innovation and accelerate improvements. IQVIA Holdings operates in more than 100 countries, with around 87,000 employees.
In 2023, IQVIA Holdings generated total revenues of $15 billion (up 4% y/y). The company manages business ...
Company Summary
Headquartered in Durham, NC., IQVIA Holdings Inc. provides advanced analytics, technology solutions and contract research services to the life sciences industry. The company was formed through the merger of IMS Health (RX) and Quintiles. The company is focused on helping healthcare clients to better serve patients by bringing in updated and innovative ideas in the process of clinical development and commercialization, speed innovation and accelerate improvements. IQVIA Holdings operates in more than 100 countries, with around 87,000 employees.
In 2023, IQVIA Holdings generated total revenues of $15 billion (up 4% y/y). The company manages business through the following three reportable segments - Technology & Analytics Solutions (formerly Commercial Solutions), Research & Development Solutions and Contract Sales & Medical Solutions (formerly Integrated Engagement Services).
Technology & Analytics Solutions Segment: This segment delivers critical information, technology solutions and real-world insights and services to the company’s life science customers. Technology & Analytics Solutions offerings include Technology solutions, Real-World Insights, Analytics and consulting services, National information offerings, Sub-national information offerings and Reference information offerings. The segment accounted for 39% of total revenues in 2023.
Research & Development Solutions Segment: This segment is focused on research and development and delivers outsourced clinical research and clinical trial related services to biopharmaceutical customers. Research & Development Solutions offerings include Project Management and Clinical Monitoring, Clinical Trial Support Services, Q Solutions, Strategic Planning and Design and Virtual Trials. The segment contributed 56% to total revenues in 2023.
Contract Sales & Medical Solutions Segment: This segment provides contract sales to the broader healthcare market as well as biopharmaceutical customers. Contract Sales & Medical Solutions offerings include Health Care Provider Engagement Services, Patient Engagement Services and Medical Affairs Services. The segment accounted for 5% of total revenues in 2023.
General Information
IQVIA Holdings Inc
2400 ELLIS ROAD
DURHAM, NC 27703
Phone: 919-998-2000
Fax: NA
Web: http://www.iqvia.com
Email: ir@iqvia.com
| Industry | Medical - Instruments |
| Sector | Medical |
| Fiscal Year End | December |
| Last Reported Quarter | 3/31/2024 |
| Earnings Date | 5/2/2024 |
EPS Information
| Current Quarter EPS Consensus Estimate | 2.47 |
| Current Year EPS Consensus Estimate | 11.09 |
| Estimated Long-Term EPS Growth Rate | 10.20 |
| Earnings Date | 5/2/2024 |
Price and Volume Information
| Zacks Rank |  |
| Yesterday's Close | 233.98 |
| 52 Week High | 261.73 |
| 52 Week Low | 167.42 |
| Beta | 1.50 |
| 20 Day Moving Average | 761,917.75 |
| Target Price Consensus | 270.83 |
| 4 Week | -7.12 |
| 12 Week | 11.16 |
| YTD | 1.51 |
| 4 Week | -4.31 |
| 12 Week | 6.94 |
| YTD | -4.46 |
| Shares Outstanding (millions) | 181.50 |
| Market Capitalization (millions) | 42,630.72 |
| Short Ratio | NA |
| Last Split Date | NA |
| Dividend Yield | 0.00% |
| Annual Dividend | $0.00 |
| Payout Ratio | 0.00 |
| Change in Payout Ratio | 0.00 |
| Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
| P/E (F1) | 21.18 |
| Trailing 12 Months | 23.00 |
| PEG Ratio | 2.07 |
| vs. Previous Year | 4.33% |
| vs. Previous Quarter | 15.72% |
| vs. Previous Year | 3.45% |
| vs. Previous Quarter | 3.53% |
| Price/Book | 7.01 |
| Price/Cash Flow | 14.92 |
| Price / Sales | 2.85 |
| 3/31/24 | NA |
| 12/31/23 | 29.32 |
| 9/30/23 | 29.60 |
| 3/31/24 | NA |
| 12/31/23 | 6.62 |
| 9/30/23 | 6.68 |
| 3/31/24 | NA |
| 12/31/23 | 0.86 |
| 9/30/23 | 0.79 |
| 3/31/24 | NA |
| 12/31/23 | 0.86 |
| 9/30/23 | 0.79 |
| 3/31/24 | NA |
| 12/31/23 | 11.54 |
| 9/30/23 | 11.58 |
| 3/31/24 | NA |
| 12/31/23 | 9.06 |
| 9/30/23 | 7.51 |
| 3/31/24 | NA |
| 12/31/23 | 9.74 |
| 9/30/23 | 9.16 |
| 3/31/24 | NA |
| 12/31/23 | 33.49 |
| 9/30/23 | 31.81 |
| 3/31/24 | NA |
| 12/31/23 | NA |
| 9/30/23 | NA |
| 3/31/24 | NA |
| 12/31/23 | 2.12 |
| 9/30/23 | 2.12 |
| 3/31/24 | NA |
| 12/31/23 | 67.94 |
| 9/30/23 | 67.98 |